10月23日 - ** 药物开发商Ventyx Biosciences VTYX.O股价盘前上涨70%至6.58美元
** Ventyx周三晚些时候表示，其口服药物VTX3232能减少肥胖症和心血管疾病患者体内与心脏病有关的关键炎症指标。
** VTYX表示，其药物在第一周就将重要的心脏风险标志物hsCRP降低了约80%。
** 与心脏风险有关的一种蛋白质 IL-6 的水平也降到了心血管风险的阈值以下--VTYX
** 该公司称，与诺和诺德公司的semaglutide联合使用可进一步降低炎症指标，但不会促进体重下降
** 截至上次收盘，该公司股价年累计上涨约 76
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.